Breakthrough treatment could unlock transplants for the Hardest-to-Match patients
NCT ID NCT05345717
Summary
This small pilot study tested whether a combination of two drugs (belatacept and a proteasome inhibitor) could safely help patients who are 'highly sensitized'—meaning their immune systems are primed to reject most donor kidneys—find a compatible donor. The goal was to lower their antibody levels so they could receive a successful transplant. Five patients with end-stage kidney disease participated in this early-phase safety and effectiveness study.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for KIDNEY TRANSPLANTATION are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
University of Chicago
Chicago, Illinois, 60637, United States
Conditions
Explore the condition pages connected to this study.